The bar is high to improve on current combination antiretroviral therapy (ART), now highly effective, safe, and simple. However, antibodies that bind the HIV envelope are able to uniquely target the virus as it seeks to enter new target cells, or as it is expressed from previously infected cells. Furthermore, the use of antibodies against HIV as a therapeutic may offer advantages. Antibodies can have long half-lives, and are being considered as partners for long-acting antiretrovirals for use in therapy or prevention of HIV infection. Early studies in animal models and in clinical trials suggest that such antibodies can have antiviral activity but, as with small-molecule antiretrovirals, the issues of viral escape and resistance will have to be addressed. Most promising, however, are the unique properties of anti-HIV antibodies: the potential ability to opsonize viral particles, to direct antibody-dependent cellular cytotoxicity (ADCC) against actively infected cells, and ultimately the ability to direct the clearance of HIV-infected cells by effector cells of the immune system. These distinctive activities suggest that HIV antibodies and their derivatives may play an important role in the next frontier of HIV therapeutics, the effort to develop treatments that could lead to an HIV cure.

中文翻译：

---

用于治疗HIV感染的HIV抗体。

可以提高目前的抗逆转录病毒疗法（ART）的水平，现在已经非常有效，安全且简单。但是，结合HIV包膜的抗体能够在病毒试图进入新的靶细胞时或从先前感染的细胞表达时，唯一地靶向病毒。此外，使用抗HIV的抗体作为治疗剂可以提供优点。抗体的半衰期很长，被认为是长效抗逆转录病毒药物的伴侣，可用于治疗或预防HIV感染。在动物模型和临床试验中的早期研究表明，此类抗体可以具有抗病毒活性，但是，与小分子抗逆转录病毒药物一样，必须解决病毒逃逸和耐药性的问题。然而，最有希望的是抗HIV抗体的独特特性：调理病毒颗粒，指导针对主动感染细胞的抗体依赖性细胞毒性（ADCC）的潜在能力，以及最终指导免疫系统效应细胞清除HIV感染细胞的能力。这些独特的活动表明，HIV抗体及其衍生物可能在HIV治疗的新领域中发挥重要作用，这是开发可能导致HIV治愈的治疗方法的努力。